Edoxaban, a direct factor Xa inhibitor, was extensively studied in the prevention and treatment of venous thromboembolism and in patients with nonvalvular atrial fibrillation (AF). The aim of this review is to focus specifically on the efficacy and safety profile of edoxaban in patients with AF from preclinical development through the phase III trial that led to regulatory approval.
Keywords: Novel oral anticoagulants; atrial fibrillation; edoxaban; factor xa inhibitor; non-vitamin K oral anticoagulants.